Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin - PubMed (original) (raw)

Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin

A Ashkenazi et al. Proc Natl Acad Sci U S A. 1991.

Abstract

Tumor necrosis factors (TNF) alpha and beta are structurally related cytokines that mediate a wide range of immunological, inflammatory, and cytotoxic effects. During bacterial infection of the bloodstream (sepsis), TNF-alpha induction by bacterial endotoxin is thought to be a major factor contributing to the cardiovascular collapse and critical organ failure that can develop. Despite antibiotic therapy, these consequences of sepsis continue to have a high mortality rate in humans. Here we describe a potent TNF antagonist, a TNF receptor (TNFR) immunoadhesin, constructed by gene fusion of the extracellular portion of human type 1 TNFR with the constant domains of human IgG heavy chain (TNFR-IgG). When expressed in transfected human cells, TNFR-IgG is secreted as a disulfide-bonded homodimer. Purified TNFR-IgG binds to both TNF-alpha and TNF-beta and exhibits 6- to 8-fold higher affinity for TNF-alpha than cell surface or soluble TNF receptors. In vitro, TNFR-IgG blocks completely the cytolytic effect of TNF-alpha or TNF-beta on actinomycin D-treated cells and is markedly more efficient than soluble TNFR (24-fold) or monoclonal anti-TNF-alpha antibodies (4-fold) in inhibiting TNF-alpha. In vitro, TNFR-IgG prevents endotoxin-induced lethality in mice when given 0.5 hr prior to endotoxin and provides significant protection when given up to 1 hr after endotoxin challenge. These results confirm the importance of TNF-alpha in the pathogenesis of septic shock and suggest a clinical potential for TNFR-IgG as a preventive and therapeutic treatment in sepsis.

PubMed Disclaimer

Similar articles

• Protection against rat endotoxic shock by p55 tumor necrosis factor (TNF) receptor immunoadhesin: comparison with anti-TNF monoclonal antibody.
  Jin H, Yang R, Marsters SA, Bunting SA, Wurm FM, Chamow SM, Ashkenazi A. Jin H, et al. J Infect Dis. 1994 Nov;170(5):1323-6. doi: 10.1093/infdis/170.5.1323. J Infect Dis. 1994. PMID: 7963738
• Inhibition of TNF by a TNF receptor immunoadhesin. Comparison to an anti-TNF monoclonal antibody.
  Haak-Frendscho M, Marsters SA, Mordenti J, Brady S, Gillett NA, Chen SA, Ashkenazi A. Haak-Frendscho M, et al. J Immunol. 1994 Feb 1;152(3):1347-53. J Immunol. 1994. PMID: 8301136
• Functional comparisons of different tumour necrosis factor receptor/IgG fusion proteins.
  Scallon BJ, Trinh H, Nedelman M, Brennan FM, Feldmann M, Ghrayeb J. Scallon BJ, et al. Cytokine. 1995 Nov;7(8):759-70. doi: 10.1006/cyto.1995.0091. Cytokine. 1995. PMID: 8664442
• Lymphotoxin-alpha-deficient and TNF receptor-I-deficient mice define developmental and functional characteristics of germinal centers.
  Matsumoto M, Fu YX, Molina H, Chaplin DD. Matsumoto M, et al. Immunol Rev. 1997 Apr;156:137-44. doi: 10.1111/j.1600-065x.1997.tb00965.x. Immunol Rev. 1997. PMID: 9176705 Review.
• [Cachectin or TNF (tumor necrosis factor): clinical implications].
  Romieu M, Riche F, Bousseau A, Szekeli B, Schurando P, Briard C, Payen D. Romieu M, et al. Ann Fr Anesth Reanim. 1990;9(6):525-35. doi: 10.1016/s0750-7658(05)80224-2. Ann Fr Anesth Reanim. 1990. PMID: 2278419 Review. French.

Cited by

• Interferon gamma signals via a high-affinity multisubunit receptor complex that contains two types of polypeptide chain.
  Marsters SA, Pennica D, Bach E, Schreiber RD, Ashkenazi A. Marsters SA, et al. Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5401-5. doi: 10.1073/pnas.92.12.5401. Proc Natl Acad Sci U S A. 1995. PMID: 7777519 Free PMC article.
• Binding efficiency of protein-protein complexes.
  Day ES, Cote SM, Whitty A. Day ES, et al. Biochemistry. 2012 Nov 13;51(45):9124-36. doi: 10.1021/bi301039t. Epub 2012 Nov 1. Biochemistry. 2012. PMID: 23088250 Free PMC article.
• Acute respiratory distress syndrome in the septic surgical patient.
  Balibrea JL, Arias-Díaz J. Balibrea JL, et al. World J Surg. 2003 Dec;27(12):1275-84. doi: 10.1007/s00268-003-7258-3. Epub 2003 Oct 28. World J Surg. 2003. PMID: 14574489 Review.
• Prevention and treatment of lethal murine endotoxemia by the novel immunomodulatory agent MFP-14.
  Nicoletti F, Di Marco R, Sacerdote P, Meroni P, Mangano K, Edwards C 3rd, Bartorelli A, Bendtzen K, Panerai A. Nicoletti F, et al. Antimicrob Agents Chemother. 2001 May;45(5):1591-4. doi: 10.1128/AAC.45.5.1591-1594.2001. Antimicrob Agents Chemother. 2001. PMID: 11302837 Free PMC article.
• Unimpaired autoreactive T-cell traffic within the central nervous system during tumor necrosis factor receptor-mediated inhibition of experimental autoimmune encephalomyelitis.
  Körner H, Goodsall AL, Lemckert FA, Scallon BJ, Ghrayeb J, Ford AL, Sedgwick JD. Körner H, et al. Proc Natl Acad Sci U S A. 1995 Nov 21;92(24):11066-70. doi: 10.1073/pnas.92.24.11066. Proc Natl Acad Sci U S A. 1995. PMID: 7479938 Free PMC article.

References

1. 1. EMBO J. 1991 Apr;10(4):827-36 - PubMed
2. 1. N Engl J Med. 1988 Aug 18;319(7):397-400 - PubMed
3. 1. N Engl J Med. 1991 Feb 14;324(7):486-8 - PubMed
4. 1. N Engl J Med. 1991 Feb 14;324(7):429-36 - PubMed
5. 1. Proc Natl Acad Sci U S A. 1990 Nov;87(21):8331-5 - PubMed

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Europe PubMed Central
  • PubMed Central

• Other Literature Sources

  • The Lens - Patent Citations Database